The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Open accessAbstract
BACKGROUND: The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown. METHODS: In an integrated study with separate induction and maintenance trials, we assessed intravenous vedolizumab therapy (300 mg) in adults with active Crohn's disease. In the induction trial, 368 patients were randomly assigned to receive vedolizumab or placebo at weeks 0 and 2 (cohort 1), and 747 patients received open-label vedolizumab at weeks 0 and 2 (cohort 2); disease status was assessed at week 6. In the maintenance trial, 461 patients who had had a response to vedolizumab were randomly assigned to receive placebo or vedolizumab every 8 or 4 weeks until week 52. RESULTS: At week 6, a total of 14.5% of the patients in cohort 1 who received vedolizumab and 6.8% who received placebo were in clinical remission (i.e., had a score on the Crohn's Disease Activity Index [CDAI] of ≤150, with scores ranging from 0 to approximately 600 and higher scores indicating greater disease activity) (P=0.02); a total of 31.4% and 25.7% of the patients, respectively, had a CDAI-100 response (≥100-point decrease in the CDAI score) (P=0.23). Among patients in cohorts 1 and 2 who had a response to induction therapy, 39.0% and 36.4% of those assigned to vedolizumab every 8 weeks and every 4 weeks, respectively, were in clinical remission at week 52, as compared with 21.6% assigned to placebo (P<0.001 and P=0.004 for the two vedolizumab groups, respectively, vs. placebo). Antibodies against vedolizumab developed in 4.0% of the patients. Nasopharyngitis occurred more frequently, and headache and abdominal pain less frequently, in patients receiving vedolizumab than in patients receiving placebo. Vedolizumab, as compared with placebo, was associated with a higher rate of serious adverse events (24.4% vs. 15.3%), infections (44.1% vs. 40.2%), and serious infections (5.5% vs. 3.0%). CONCLUSIONS: Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolizumab (rather than switching to placebo) were more likely to be in remission at week 52. Adverse events were more common with vedolizumab. (Funded by Millennium Pharmaceuticals; GEMINI 2 ClinicalTrials.gov number, NCT00783692.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationA Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Development of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,888
Self-citationColombel, J., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,245
Self-citationBaumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60026-9 · Cited by 2,154
Self-citationHanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D., Panaccione, R., Wolf, D., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,715
Self-citationDignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Self-citationThe Medical Dictionary for Regulatory Activities (MedDRA)
Brown, E. G., Wood, L., & Wood, S. (1999) · Drug Safety · doi:10.2165/00002018-199920020-00002 · Cited by 1,390
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J. V., Sandrock, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107829 · Cited by 1,242
Self-citationManagement of Crohn's Disease in Adults
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.168 · Cited by 1,173
Self-citationCertolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Self-citationUstekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
Sandborn, W. J., Gasink, C., Gao, L.-L., Blank, M. A., Johanns, J., Guzzo, C., Sands, B. E., Hanauer, S. B., Targan, S., Rutgeerts, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203572 · Cited by 1,134
Self-citationBeaugerie, L., Brousse, N., Bouvier, A. M., Colombel, J. F., Lémann, M., Cosnes, J., Hébuterne, X., Cortot, A., Bouhnik, Y., Gendre, J. P., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61302-7 · Cited by 1,115
Self-citationMaintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
Self-citationRisk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease
Toruner, M., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., Orenstein, R., Sandborn, W. J., Colombel, J., & Egan, L. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.012 · Cited by 1,017
Self-citationSandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Colombel, J.-F., Panaccione, R., D'Haens, G., Li, J., Rosenfeld, M. R., Kent, J. D., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00159 · Cited by 965
Self-citationAzathioprine and 6-Mercaptopurine in Crohn Disease: A Meta-Analysis
Pearson, D. C., May, G. R., Fick, G. H., & Sutherland, L. R. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-2-199507150-00009 · Cited by 950
Natalizumab Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G., Hanauer, S. B., Lawrance, I. C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043335 · Cited by 927
Self-citationNatalizumab for Active Crohn's Disease
Ghosh, S., Goldin, E., Gordon, F. H., Malchow, H. A., Rask-Madsen, J., Rutgeerts, P., Vyhnálek, P., Zádorová, Z., Palmer, T., & Donoghue, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020732 · Cited by 808
Self-citationEvaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054693 · Cited by 790
Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors
Egli, A., Infanti, L., Dumoulin, A., Buser, A., Samaridis, J., Stebler, C., Gosert, R., & Hirsch, H. H. (2009) · The Journal of Infectious Diseases · doi:10.1086/597126 · Cited by 781
Sandborn, W. J., Feagan, B. G., Fedorak, R. N., Scherl, E., Fleisher, M. R., Katz, S., Johanns, J., Blank, M., & Rutgeerts, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.014 · Cited by 753
Self-citationSands, B. E., Feagan, B. G., Rutgeerts, P., Colombel, J.-F., Sandborn, W. J., Sy, R., D’Haens, G., Ben-Horin, S., Xu, J., Rosario, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.05.008 · Cited by 715
Self-citationTreatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Dubé, R., Cohen, A., Steinhart, A. H., Landau, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042982 · Cited by 692
Self-citationSandborn, W. J., Feagan, B. G., Hanauer, S. B., Lochs, H., Löfberg, R., Modigliani, R., Present, D. H., Rutgeerts, P., Schölmerich, J., Stange, E. F., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.31072 · Cited by 686
Self-citationNatalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
Targan, S. R., Feagan, B. G., Fedorak, R. N., Lashner, B. A., Panaccione, R., Present, D. H., Spehlmann, M. E., Rutgeerts, P. J., Tulassay, Z., Volfova, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.024 · Cited by 614
Self-citationKnowles, W. A., Pipkin, P., Andrews, N., Vyse, A., Minor, P., Brown, D. W. G., & Miller, E. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10450 · Cited by 586
Peyrin–Biroulet, L., Deltenre, P., de Suray, N., Branche, J., Sandborn, W. J., & Colombel, J. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.03.014 · Cited by 577
Self-citationPadgett, B. L., & Walker, D. L. (1973) · Journal of Infectious Diseases · doi:10.1093/infdis/127.4.467 · Cited by 479
Soler, D., Chapman, T., Yang, L.-L., Wyant, T., Egan, R., & Fedyk, E. R. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.153973 · Cited by 456
Lichtenstein, G. R., Abreu, M. T., Cohen, R., & Tremaine, W. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.048 · Cited by 417
Papp, K. A., Griffiths, C. E. M., Gordon, K., Lebwohl, M., Szapary, P. O., Wasfi, Y., Chan, D., Hsu, M.-C., Ho, V., Ghislain, P. D., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12214 · Cited by 415
Lichtenstein, G. R., Sbreu, M. T., Cohen, R. D., & Tremaine, W. J. (2006) · PubMed · Cited by 371
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Cohen, A., Bitton, A., Baker, J., Dubé, R., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.06.007 · Cited by 285
Self-citationLichtenstein, G. R., Rutgeerts, P., Sandborn, W. J., Sands, B. E., Diamond, R. H., Blank, M., Montello, J., Tang, L., Cornillie, F., & Colombel, J.-F. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.89 · Cited by 228
Self-citationParikh, A., Leach, T., Wyant, T., Scholz, C., Sankoh, S., Mould, D. R., Ponich, T., Fox, I., & Feagan, B. G. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21896 · Cited by 210
Self-citationThe limitations of corticosteroid therapy in Crohn’s disease
Rutgeerts, P. J. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01060.x · Cited by 166
Self-citationNovel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin
Sandborn, W. J., & Yednock, T. A. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.08703.x · Cited by 91
Self-citationBalancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease
Sandborn, W. J., & Loftus, E. V. (2004) · Gut · doi:10.1136/gut.2003.020552 · Cited by 71
Self-citationUse of thiopurines in inflammatory bowel disease: Safety issues
Konidari, A., & El‐Matary, W. (2014) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v5.i2.63 · Cited by 56
Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials.
Naber, A. H. J., & de Jong, D. J. (2003) · PubMed · Cited by 46
Maintenance treatment of Crohn's disease
Biancone, L., Tosti, C., Fina, D., Fantini, M. C., Nigris, F. D., Geremia, A., & Pallone, F. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.17.s2.20.x · Cited by 34
Cited by
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,888
Self-citationTorres, J., Mehandru, S., Colombel, J.-F., & Peyrin-Biroulet, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31711-1 · Cited by 2,682
Self-citationLamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
de Lange, K. M., Moutsianas, L., Lee, J. C., Lamb, C. A., Luo, Y., Kennedy, N. A., Jostins, L., Rice, D. L., Gutierrez-Achury, J., Ji, S.-G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3760 · Cited by 1,445
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2018.27 · Cited by 1,421
Self-citation
Metadata
- Authors
- Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., Fox, I., Rosario, M., Sankoh, S., Xu, J., Stephens, K., Milch, C., & Parikh, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-22
- Volume
- 369
- Issue
- 8
- Pages
- 711-721
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2077531651
- Cited by
- 2,719
- References
- 45
- FWCI
- 82.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.